Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder

NCT ID: NCT02335853

Last Updated: 2015-01-12

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2015-12-31

Brief Summary

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder.

Detailed Description

Overactive bladder is a clinical syndrome characterized urgency, frequency and nocturia. Infection or other obvious causes must be excluded. The overactive bladder is loss of inhibition of the detrusor muscle during the filling or emptying of the bladder.

Specific receptors and neurotransmitters have role in development of overactive bladder. These includes adrenergic, cholinergic, non-adrenergic, non-cholinergic receptors and interstitial cells.

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder. The investigators believe that our findings will shed light on treatment.

Conditions

Overactive Bladder

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

women with metabolic syndrome and overactive bladder

women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:

1. Abdominal obesity, defined as a waist circumference in men ≥88 cm

2. Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides

3. Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C

4. Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure

5. Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose

No interventions assigned to this group

women with overactive bladder

women with urinary urgency+frequency+nocturia

No interventions assigned to this group

healthy control group

women not overactive bladder and metabolic syndrome

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• women with urgency, nocturia and frequency
• Abdominal obesity, defined as a waist circumference in men ≥88 cm
• Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
• Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C
• Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
• Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose

Exclusion Criteria

• Chronic obstructive pulmonary disease allergy
• Psychiatric disorders
• Urinary tract infection
• Neurological diseases
• Metabolic diseases
• Pure stress or mixed urinary incontinence
• History of pelvic surgery
• Diabetes mellitus

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Bakirkoy Dr Sadi Konuk Training and Research Hospital

Istanbul, Bakirkoy, Turkey (Türkiye)

Site Status: RECRUITING

Countries

Turkey (Türkiye)

Facility Contacts

hediye dagdeviren, md

Role: primary

hediyedagdeviren@gmail.com

5536161385

Other Identifiers

2014/11/02

Identifier Type: -

Identifier Source: org_study_id